TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer

Gynecologic Oncology

Volumn 132, Issue 3, 2014, Pages 752-757

  Zhang, Guo Nan ^a,b,c   Liu, Hong ^a   Huang, Jian Ming ^a   Wang, Ling ^a,b   Zhao, Jing Sha ^a,c   Li, Chao ^a,b   Mi, Kun ^a   Zhu, Yi ^a   Cheng, Jia ^a   Zha, Xiao ^a  

^a SICHUAN CANCER HOSPITAL   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

^c SOUTHWEST MEDICAL UNIVERSITY   (China)

Author keywords

K351N mutation; Neoadjuvant chemotherapy; Ovarian cancer; TP53

Indexed keywords

CISPLATIN; GENOMIC DNA; PACLITAXEL; PROTEIN P53;

ADULT; ADVANCED CANCER; ALLELE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; DNA SEQUENCE; DNA TEMPLATE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MIDDLE AGED; MISSENSE MUTATION; OUTCOME ASSESSMENT; OVARY CARCINOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE RISK; RETROSPECTIVE STUDY;

K351N MUTATION; NEOADJUVANT CHEMOTHERAPY; OVARIAN CANCER; TP53;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, P53; HUMANS; MIDDLE AGED; MUTATION, MISSENSE; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84896404660     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.01.028     Document Type: Article

References (40)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 1 2013 11 30
2. P.A. Vasey, J. Herrstedt, S. Jelic, and E.G.T. Force ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of epithelial ovarian carcinoma Ann Oncol 16 Suppl. 1 2005 i13 i15
3. R.P. Perez, T.C. Hamilton, R.F. Ozols, and R.C. Young Mechanisms and modulation of resistance to chemotherapy in ovarian cancer Cancer 71 4 Suppl. 1993 1571 1580
4. L. Kelland The resurgence of platinum-based cancer chemotherapy Nat Rev Cancer 7 8 2007 573 584
5. S. Cornelis, B. Van Calster, F. Amant, K. Leunen, A.G. van der Zee, and I. Vergote Role of neoadjuvant chemotherapy in the management of stage IIIC-IV ovarian cancer: survey results from the members of the European Society of Gynecological Oncology Int J Gynecol Cancer 22 3 2012 407 416
6. M.J. Worley Jr., S.H. Guseh, J.A. Rauh-Hain, K.A. Williams, M.G. Muto, and C.M. Feltmate et al. Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery? Gynecol Oncol 129 1 2013 69 73
7. J. Morrison, K. Haldar, S. Kehoe, and T.A. Lawrie Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer Cochrane Database Syst Rev 8 2012 CD005343
8. I. Vergote, C.G. Trope, F. Amant, G.B. Kristensen, T. Ehlen, and N. Johnson et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer N Engl J Med 363 10 2010 943 953
9. I. Vergote, C.G. Trope, F. Amant, T. Ehlen, N.S. Reed, and A. Casado Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer J Clin Oncol 29 31 2011 4076 4078
10. I. Vergote, F. Amant, G. Kristensen, T. Ehlen, N.S. Reed, and A. Casado Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer Eur J Cancer 47 Suppl. 3 2011 S88 S92
11. D.S. Chi, F. Musa, F. Dao, O. Zivanovic, Y. Sonoda, and M.M. Leitao et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT) Gynecol Oncol 124 1 2012 10 14
12. D. Jelovac, and D.K. Armstrong Recent progress in the diagnosis and treatment of ovarian cancer CA Cancer J Clin 61 3 2011 183 203
13. J.A. Rauh-Hain, C.C. Nitschmann, M.J. Worley Jr., L.S. Bradford, R.S. Berkowitz, and J.O. Schorge et al. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma Gynecol Oncol 129 1 2013 63 68
14. R. Agarwal, and S.B. Kaye Ovarian cancer: strategies for overcoming resistance to chemotherapy Nat Rev Cancer 3 7 2003 502 516
15. J.S. Skilling, R.C. Squatrito, J.P. Connor, T. Niemann, and R.E. Buller p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines Gynecol Oncol 60 1 1996 72 80
16. S. Laframboise, W. Chapman, J. McLaughlin, and I.L. Andrulis p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance Cancer J 6 5 2000 302 308
17. A. Gadducci, C. Di Cristofano, M. Zavaglia, L. Giusti, M. Menicagli, and S. Cosio et al. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome Anticancer Res 26 1B 2006 687 693
18. A. Reles, W.H. Wen, A. Schmider, C. Gee, I.B. Runnebaum, and U. Kilian et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer Clin Cancer Res 7 10 2001 2984 2997
19. P. Perego, M. Giarola, S.C. Righetti, R. Supino, C. Caserini, and D. Delia et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems Cancer Res 56 3 1996 556 562
20. A.A. Ahmed, D. Etemadmoghadam, J. Temple, A.G. Lynch, M. Riad, and R. Sharma et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary J Pathol 221 1 2010 49 56
21. M. Muscolini, E. Montagni, S. Caristi, T. Nomura, R. Kamada, and S. Di Agostino et al. Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain Cell Cycle 8 20 2009 3396 3405
22. J. Turanek, A. Kasna, D. Zaluska, J. Neca, V. Kvardova, and P. Knotigova et al. New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes Anticancer Drugs 15 5 2004 537 543
23. B.C. Behrens, T.C. Hamilton, H. Masuda, K.R. Grotzinger, J. Whang-Peng, and K.G. Louie et al. Characterization of a cis-diamminedichloroplatinum(II)- resistant human ovarian cancer cell line and its use in evaluation of platinum analogues Cancer Res 47 2 1987 414 418
24. H. Masuda, R.F. Ozols, G.M. Lai, A. Fojo, M. Rothenberg, and T.C. Hamilton Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines Cancer Res 48 20 1988 5713 5716
25. M. Muscolini, E. Montagni, V. Palermo, S. Di Agostino, W. Gu, and S. Abdelmoula-Souissi et al. The cancer-associated K351N mutation affects the ubiquitination and the translocation to mitochondria of p53 protein J Biol Chem 286 46 2011 39693 39702
26. R. Kamada, T. Nomura, C.W. Anderson, and K. Sakaguchi Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation J Biol Chem 286 1 2011 252 258
27. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, and R. Ford et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2 2009 228 247
28. L.M. McShane, D.G. Altman, W. Sauerbrei, S.E. Taube, M. Gion, and G.M. Clark Statistics Subcommittee of the NCIEWGoCD: reporting recommendations for tumor marker prognostic studies J Clin Oncol 23 36 2005 9067 9072
29. I. Vergote, G.J. Rustin, E.A. Eisenhauer, G.B. Kristensen, E. Pujade-Lauraine, and M.K. Parmar et al. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup J Natl Cancer Inst 92 18 2000 1534 1535
30. R.E. Bristow, E.L. Eisenhauer, A. Santillan, and D.S. Chi Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction Gynecol Oncol 104 2 2007 480 490
31. S.L. Cooke, and J.D. Brenton Evolution of platinum resistance in high-grade serous ovarian cancer Lancet Oncol 12 12 2011 1169 1174
32. L. Galluzzi, L. Senovilla, I. Vitale, J. Michels, I. Martins, and O. Kepp et al. Molecular mechanisms of cisplatin resistance Oncogene 31 15 2012 1869 1883
33. P. Branch, M. Masson, G. Aquilina, M. Bignami, and P. Karran Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells Oncogene 19 2000 3138 3145
34. X. Lin, and S.B. Howell DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance Mol Cancer Ther 5 5 2006 1239 1247
35. X. Xiao, D.W. Melton, and C. Gourley Mismatch repair deficiency in ovarian cancer - molecular characteristics and clinical implications Gynecol Oncol 132 2 2014 506 512
36. S. Aebi, B. Kurdi-Haidar, R. Gordon, B. Cenni, H. Zheng, and D. Fink et al. Loss of DNA mismatch repair in acquired resistance to cisplatin Cancer Res 56 13 1996 3087 3090
37. M.M. de las Alas, S. Aebi, D. Fink, S.B. Howell, and G. Los Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance J Natl Cancer Inst 89 20 1997 1537 1541
38. C. Gercel-Taylor, J.J. Scobee, and D.D. Taylor Effect of chemotherapy on the mutation frequency of ovarian cancer cells at the HPRT locus Anticancer Res 25 3B 2005 2113 2117
39. S.C. Righetti, P. Perego, E. Corna, M.A. Pierotti, and F. Zunino Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection Cell Growth Differ 10 7 1999 473 478
40. D.W. Shen, L.M. Pouliot, M.D. Hall, and M.M. Gottesman Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes Pharmacol Rev 64 3 2012 706 721